Pharma Spends What on eSales?
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 17, 2014 Category: Pharma Commentators Tags: eSampling Sales and Sales Reps Source Type: blogs
Why the FDA Approved Zohydro
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 17, 2014 Category: Pharma Commentators Tags: Drug Safety FDA Legal/Regulatory Source Type: blogs
Doctor Glaxo is here to teach you
GlaxoSmithKline Plc (GSK) plans to hire doctors to educate their peers about its drugs instead of paying external speakers, a further change to its marketing practices following a record fraud settlement in the U.S.The drugmaker is also investing in improving its multichannel marketing strategy through media such as online streaming of educational content, Deirdre Connelly, head of Glaxo’s U.S. pharmaceuticals business, said in an interview in Philadelphia. The changes come at a time when London-based Glaxo is introducing products recently approved to treat skin cancer, HIV and respiratory diseases.Glaxo has been re...
Source: PharmaGossip - March 17, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Novartis gave doctors thousands to prescribe pills, feds allege
By KATHLEEN KERR kathleen.kerr@newsday.comDr. Howard Brand says he had one goal when he gave a speech at a Miami hotel in the early 2000s -- to tout the diabetes pill Starlix for the pharmaceutical company Novartis.The giant Swiss drugmaker, which reported $57.9 billion in global sales in 2013, paid the Stony Brook endocrinologist $1,500 for his talk at a doctors' meeting, Brand said in an interview. Novartis also paid for Brand's airfare and his weekend hotel stay, he said."It was self-serving, but I also thought it was a benefit to patients," said Brand, who explained that his expenses-paid weekend in Flo...
Source: PharmaGossip - March 16, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
A hell of a mesh
J&J Lawsuit Sheds Light on Link Between Doctors and Device MakersOne lawsuit taking legal precedence on Johnson & Johnson’s (NYSE:JNJ) docket dates back to March 2005, when the pharmaceutical giant’s Ethicon unit introduced the Gynecare Prolift transvaginal mesh device. Several years later, the company’s 2007 annual report touted the device as an “innovative and effective surgical option” for weakened pelvic muscles.The problem was the U.S. Food and Drug Administration did not approve the device for another three years after its initial release. At the time, the company said ...
Source: PharmaGossip - March 16, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Novartis gave doctors thousands to prescribe pills, feds allege
GooglePin ItOriginally published: March 15, 2014 7:41 PMUpdated: March 15, 2014 8:26 PMBy KATHLEEN KERR kathleen.kerr@newsday.comAn illuminated logo sits above windows at Novartis AG's headquarters in Basel, Switzerland, on Tuesday, July, 16, 2013. (Credit: Bloomberg / Gianluca Colla)Dr. Howard Brand says he had one goal when he gave a speech at a Miami hotel in the early 2000s -- to tout the diabetes pill Starlix for the pharmaceutical company Novartis.The giant Swiss drugmaker, which reported $57.9 billion in global sales in 2013, paid the Stony Brook endocrinologist $1,500 for his talk at a doctors'...
Source: PharmaGossip - March 16, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
AstraZeneca has now changed its focus, moving from "milestone seeking
behaviour" to "truth seeking behaviour"
http://www.pharmaphorum.com/news/astrazeneca-now-led-by-science-not-commercial-milestones-says-rd-head? (Source: PharmaGossip)
Source: PharmaGossip - March 15, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Antibiotics - Elizabeth Warren isn't satisfied
New voluntary rules to limit the use of antibiotics in agriculture aren’t enough to satisfy Senator Elizabeth Warren (D-Mass.). The Food and Drug Administration announced the rules in December, asking pharmaceutical makers to relabel drugs so that they require a prescription and asking farmers to use them only to treat, control, and prevent disease in livestock, not to add weight. But Warren is now questioning the effectiveness of the FDA’s plan.The guidelines resulted from concern at the agency that overuse of antibiotics on farms might create drug-resistant bacteria, which can infect not only livestock but also human...
Source: PharmaGossip - March 14, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
What ails Big Pharma?
By Katherine EbanOne of America's most far-seeing companies, Vertex Pharmaceuticals, the biopharmaceutical startup so memorably chronicled in journalist Barry Werth's classic book, The Billion Dollar Molecule: The Quest for the Perfect Drug, is back.Or rather, twenty years later, Werth is back with the sequel, The Antidote: Inside the World of New Pharma. The book revisits Vertex as the company grows into adolescence and actually achieves its goal of bringing a drug to market. Even though there is less drama this time and more mundane human-resource type challenges, Werth's excellent writing takes the reader deep into the ...
Source: PharmaGossip - March 13, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Red GOP States Addled by Adderall
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 12, 2014 Category: Pharma Commentators Tags: Adderall ADHD Source Type: blogs
Teva and The Reinstein Connection
The U.S. business of Teva Pharmaceuticals Industries Ltd. and a subsidiary have agreed to pay $27.6 million to settle allegations of improper payments, the Justice Department said Tuesday.Teva unit Ivax LLC in 2003 allegedly paid a doctor in Illinois to switch his patients to a generic antipsychotic medication the business produced, according to the Justice Department.Teva, an Israeli company specializing in generic drugs, acquired Ivax for more than $7 billion in early 2006.The physician, Michael J. Reinstein, received payments, as well as a Miami vacation for his family and several employees, under an illegal consulting ...
Source: PharmaGossip - March 11, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
The One Thousand Dollar Pill
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences. A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" treatment when compared with older drugs for the blood borne virus. The vote was part of a broader review of new hepatitis C drugs by the California Technology Assessment Forum. The insurer-affiliated group assesses the costs and effectiveness of new medical treatments. The group estimates th...
Source: PharmaGossip - March 11, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
NJ jury orders drugmaker Roche to pay $1.5M at Accutane trial
Drugmaker Roche must pay more than $1.5 million in damages to a woman who developed bowel disease after using the company’s Accutane acne medicine, a jury ruled in her retrial.Officials of Basel, Switzerland-based Roche failed to properly warn Kamie Kendall’s doctors that Accutane could cause ulcerative colitis and were liable for her injuries, jurors in state court in New Jersey concluded today.It was the second trial of Kendall’s Accutane claims. A New Jersey appeals court overturned a $10.5 million verdict in 2010, ruling that a judge improperly barred Roche from using evidence about the medication’s use. Roche ...
Source: PharmaGossip - March 11, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Las Vegas trial starts Monday in multibillion-dollar liability case against Actos
By CARRI GEER THEVENOTLAS VEGAS REVIEW-JOURNALTwo Clark County women are among thousands of plaintiffs across the country who have filed product liability lawsuits against the maker of the diabetes drug Actos.Delores Cipriano, 81, of Henderson and Bertha Triana, 80, of Las Vegas each filed lawsuits last year in District Court against Takeda Pharmaceuticals, a Japanese company that makes the prescription drug pioglitazone under the trade name Actos. Both women allege their bladder cancer was caused by the medication.Their cases have been combined, and their lawyers are scheduled to present opening statements to a jury this ...
Source: PharmaGossip - March 10, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
FDA's "Crimean Referendum" Putsched Aveed Through the Approval Process
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - March 7, 2014 Category: Pharma Commentators Tags: Aveed FDA Legal/Regulatory Low T testosterone Source Type: blogs
